Palatin Technologies is a biopharmaceutical company focused on the development of innovative therapies for a range of medical conditions, including sexual health disorders and other areas with unmet therapeutic needs
The company primarily works on peptide-based drug candidates, leveraging its proprietary technologies to create treatments that target specific physiological pathways. Palatin is committed to advancing its development programs through rigorous research and clinical trials, with the aim of providing effective solutions for patients and improving overall health outcomes.
Palatin Technologies (NYSE American: PTN)* just unveiled remarkable topline results from its Phase 2 study of PL8177 for ulcerative colitis (UC), demonstrating what could be a disruptive new treatment approach for this debilitating inflammatory bowel condition.
Palatin's study shows co-administering bremelanotide with tirzepatide led to greater weight loss than tirzepatide alone, with further analysis ongoing.
Palatin's PL8177 showed promising ulcerative colitis trial results, with strong clinical response rates. FDA granted orphan status to its obesity drug PL7737.
In an exciting development for the biopharma market, Palatin Technologies (NYSE: PTN)* announced that it has secured FDA orphan drug designation for PL7737, its oral melanocortin-4 receptor (MC4R) agonist, targeting obesity caused by leptin receptor deficiency. According to the company, this designation offers Palatin significant benefits, including tax credits, fee waivers, and potential seven-year market exclusivity upon approval. The company has begun toxicology studies with plans to submit an IND in Q4 2025 and expects clinical data in early 2026.
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.
Palatin Technologies: Utilizing The Melanocortin System As The Basis For Innovation In Drug Development – Targeting Inflammatory & Autoimmune Conditions, Obesity And Sexual Dysfunctions
The Dow Jones index closed slightly lower on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Palatin Technologies' results from PL9643 MELODY-1 Phase 3 trial for dry eye disease. The co-primary endpoints and secondary endpoints did not reach statistical significance.
U.S. stocks traded lower this morning, with the Dow Jones index falling around 200 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.52% to 38,770.83 while the NASDAQ fell 0.63% to 15,933.71. The S&P 500 also fell, dropping, 0.33% to 5,061.21.
